Table 6.

Cox regression analyses of validated risk factors for melanoma

	Univariate			Multivariate
Factor	HR	95% CI	p-value	HR	95% CI	p-value
Age
50 – 59	1.53	0.70 – 3.34	0.285	1.53	0.70 – 3.34	0.285
60 – 69	1.62	0.74 – 3.55	0.230	1.62	0.74 – 3.54	0.230
≥ 70	1.35	0.55 – 3.30	0.507	1.35	0.55 – 3.30	0.507
Breslow’s index
1.01 – 2.00 mm	0.79	0.39 – 1.59	0.502	0.79	0.39 – 1.59	0.502
2.01 – 4.00 mm	0.59	0.27 – 1.29	0.182	0.59	0.27 – 1.29	0.182
≥ 4.01 mm	1.55	0.61 – 3.92	0.356	1.55	0.61–3.92	0.356
Sex
female	1.72	0.98 – 3.06	0.059	1.72	0.98 – 3.06	0.059
Histologic subtype
nodular type	1.29	0.55 – 3.02	0.553	1.29	0.55 – 3.02	0.553
Mutational status
BRAF	0.46	0.20 – 1.07	0.072	0.46	0.20 – 1.07	0.072
NRAS	0.70	0.33 – 1.47	0.346	0.70	0.33 – 1.47	0.346
SLNB
positive	2.65	1.15 – 6.10	0.022*	2.65	1.15 – 6.10	0.022*
Treatment
targeted therapy	1.10	0.49 – 2.46	0.821	1.10	0.49 – 2.46	0.821
ICB	0.17	0.06 – 0.48	0.001***	0.17	0.06 – 0.48	0.001***
chemotherapy	0.57	0.25 – 1.29	0.175	0.57	0.25 – 1.29	0.175

Univariate and multivariate analysis on survival from the primary diagnosis (OS) of melanoma. Validated risk factors, the mutational status, and therapies were assessed with Cox proportional hazard regression. The references for each factor were age < 50 years, male sex, Breslow’s thickness < 1.00 mm, negative SLNB status, WT for BRAF and NRAS, non-nodular subtype, and no systemic therapy. Hazard ratios (HR) for death and 95% confidence intervals (CI) are indicated; SLNB sentinel lymph node biopsy, ICB immune checkpoint blockade; *p < 0.05, ***p < 0.001